ETF Education Report: F/M EMERALD LIFE SCIENCES INNOVATION ETF (LFSC)

What this ETF is trying to do

The F/M EMERALD LIFE SCIENCES INNOVATION ETF (ticker: LFSC) is an exchange-traded fund that focuses on the life sciences sector. Based on its top holdings, it invests in various companies involved in therapeutics and medical technology.

What the numbers show

The current price of LFSC is $46.79. Looking back at historical performance, we can see significant movement in the share price:

• One-Year Performance: The one-year price return was approximately 80.95%. This measures only the change in the share price. The one-year total return was also approximately 80.95%, which includes distributions (though none were detected here).

• Year-to-Date (YTD) Performance: The YTD price return is approximately 27.79%. The YTD total return is also approximately 27.79%.

To understand the growth, we can look at an estimated price from roughly one year ago, which was approximately $25.86. For example, if you had invested $10,000 into this ETF one year ago based on these share prices, your investment would have grown to approximately $18,095 before any distributions were added.

Income and distribution explanation

Some investors look for ETFs that pay out regular cash, known as distributions. For LFSC, the distribution yield is 0%. No distributions were detected over the last 12 months. This means the fund has not been providing cash income to shareholders during this period.

NAV erosion explanation

"NAV erosion" refers to a situation where the value of the underlying assets in the ETF decreases significantly. When an ETF's share price drops, it can sometimes be a sign of NAV erosion. However, for LFSC, the erosion-risk score is 100, and the label indicates "No price erosion detected." There is no severe erosion-risk flag for this fund.

Top Holdings

The following are the top holdings in this ETF (note that this list is partial):

• TRAVERE THERAPEUTICS INC: 8.01%

• SPYRE THERAPEUTICS INC: 7.45%

• COGENT BIOSCIENCES INC: 7.16%

• LIVANOVA PLC: 6.59%

• GUARDANT HEALTH INC: 5.89%

• CORCEPT THERAPEUTICS INC: 5.39%

• MIRUM PHARMACEUTICALS INC: 5.06%

• BILLIONTOONE INC: 4.43%

• CYTOKINETICS INC: 4.06%

• TREVI THERAPEUTICS INC: 3.41%

*Holdings data was last updated on August 20, 2026. Please remember that holdings can change over time.*

Pros

• The ETF has shown strong share-price growth over the past year.

• The erosion-risk measurements suggest a "good" status with no detected price erosion.

Cons

• The ETF does not currently provide cash distributions (income).

• It is focused on a specific sector (life sciences), which may behave differently than the broader market.

Beginner takeaway

LFSC has experienced significant share-price appreciation over the last year. While it has not provided regular cash income through distributions, its price return has been high. Always remember that past performance does not guarantee what will happen in the future.